Pfizer Inc. is gearing up to report its first-quarter 2026 earnings on May 5, with expectations of a 19.6% decline to $0.74 per share, despite analysts forecasting a slight revenue increase to $13.82 billion. The company has exceeded earnings expectations in the last four quarters, but anticipates a $1.5 billion revenue drop from impending loss of exclusivity on key drugs by 2030. As it shifts focus from its reduced COVID business, Pfizer expects to have eight blockbuster oncology products by 2030 and has invested significantly in acquisitions, totaling approximately $9 billion in 2025.
“Metsera · has been acquired by · Pfizer · Pfizer”
“Analysts · see Pfizer (PFE) delivering Q1 EPS · $0.72 · true”
“Pfizer Inc. (NYSE:PFE) · is one of the · 10 Best Medical Stocks to Buy Under $30”
“Pfizer Inc. (NYSE:PFE) · announced · the US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for Priority Review”
“Pfizer Inc. (NYSE:PFE) · is a leading pharmaceutical company that focuses on the discovery, development, and manufacture of · healthcare products, medicines, and vaccines”
“Pfizer · reached settlements with · three generic drugmakers · Hikma, Cipla, and Dexcel”
“Pfizer Inc. (NYSE:PFE) · is included among · 10 Innovative Dividend Stocks to Buy Right Now”
“Morgan Stanley · maintains · Pfizer (PFE) · Equal Weight”
“Morgan Stanley · sets a price target on · Pfizer Inc. (NYSE:PFE) · $28”
“Pfizer · reached a settlement with · all three Vyndamax generic filers”
“Pfizer · developed a form of · santonin · used to treat intestinal worms”
“Pfizer Inc. (NYSE:PFE) · is a · research-based global biopharmaceutical company”
.svg&width=160)